D. E. Shaw & Co. Inc. Lowers Stake in IDEAYA Biosciences, Inc. (NASDAQ:IDYA)

D. E. Shaw & Co. Inc. decreased its stake in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA) by 68.2% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 180,676 shares of the company’s stock after selling 387,055 shares during the period. D. E. Shaw & Co. Inc. owned 0.21% of IDEAYA Biosciences worth $4,643,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of IDYA. R Squared Ltd acquired a new position in IDEAYA Biosciences during the fourth quarter worth approximately $35,000. Daiwa Securities Group Inc. increased its position in IDEAYA Biosciences by 44.0% during the fourth quarter. Daiwa Securities Group Inc. now owns 2,792 shares of the company’s stock worth $72,000 after purchasing an additional 853 shares during the last quarter. KBC Group NV increased its position in IDEAYA Biosciences by 84.6% during the fourth quarter. KBC Group NV now owns 4,197 shares of the company’s stock worth $108,000 after purchasing an additional 1,923 shares during the last quarter. Cibc World Markets Corp acquired a new position in IDEAYA Biosciences during the fourth quarter worth approximately $203,000. Finally, Mariner LLC increased its position in IDEAYA Biosciences by 9.8% during the fourth quarter. Mariner LLC now owns 9,775 shares of the company’s stock worth $251,000 after purchasing an additional 869 shares during the last quarter. Institutional investors and hedge funds own 98.29% of the company’s stock.

Analysts Set New Price Targets

Separately, Stephens reaffirmed an “overweight” rating and set a $50.00 price target on shares of IDEAYA Biosciences in a research report on Friday, February 14th. Two equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $54.27.

IDEAYA Biosciences Trading Up 2.9%

Shares of IDYA stock opened at $17.82 on Friday. The company has a market capitalization of $1.56 billion, a PE ratio of -5.40 and a beta of 0.26. The firm has a fifty day simple moving average of $17.64 and a 200-day simple moving average of $22.22. IDEAYA Biosciences, Inc. has a twelve month low of $13.45 and a twelve month high of $44.42.

IDEAYA Biosciences (NASDAQ:IDYA) last announced its earnings results on Tuesday, May 6th. The company reported ($0.82) earnings per share for the quarter, missing the consensus estimate of ($0.75) by ($0.07). During the same quarter last year, the firm posted ($0.53) EPS. Equities research analysts predict that IDEAYA Biosciences, Inc. will post -3.07 EPS for the current year.

About IDEAYA Biosciences

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.